Overview

A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population. To explore relationships between exposure to Ro 24-7429 and its metabolites with its antitumor and antiviral activities and drug toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche